Method for determining radiotherapy sensitivity of nasopharyngeal carcinoma

Abstract

A method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma. The molecular marker is Survivin, and determining Survivin to be the molecular marker for the radiotherapy sensitivity of nasopharyngeal carcinoma comprises the following steps: step 1, literature research; step 2, a cell line experiment; step 3, an animal model experiment; step 4, clinical sample verification; step 5, statistical analysis; step 6, optimization of a method for evaluating the radiotherapy sensitivity; step 7, mechanism research; step 8, construction of a prediction model for radiotherapy sensitivity; and step 9, multi-center research verification.

Description

A method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma Technical Field

[0001] The present invention relates to the technical field of radiotherapy for nasopharyngeal carcinoma, and in particular to a method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma. Background Art

[0002] Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in the mucosal tissue of the nasopharynx, usually in the posterior wall of the nasopharynx. This type of cancer often causes throat discomfort, facial lumps, hearing loss, nasal congestion, and nosebleeds. Treatment for NPC usually includes radiation therapy, chemotherapy, and surgery. Common symptoms of NPC include nasal congestion, runny nose, nosebleeds, facial pain or pressure, sore throat, hoarseness, difficulty swallowing, and a lump in the neck. Early-stage NPC may have no obvious symptoms and is therefore often overlooked.

[0003] Summary of the Invention

[0004] The technical problem solved by the present invention is that the existing methods for determining the radiotherapy sensitivity of nasopharyngeal carcinoma are poorly effective in determining the radiotherapy sensitivity of nasopharyngeal carcinoma and cannot effectively determine the radiotherapy sensitivity of nasopharyngeal carcinoma based on molecular markers, which is not conducive to the diagnosis and treatment of nasopharyngeal carcinoma in patients. Therefore, we propose a method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma to solve the above problem.

[0005] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0006] As a preferred embodiment of the method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma described in the present invention, wherein: the molecular marker is Survivin, and the determination of Survivin as a molecular marker for the radiotherapy sensitivity of nasopharyngeal carcinoma includes the following steps: step 1, literature research; step 2, cell line experiments; step 3, animal model experiments; step 4, clinical sample verification; step 5, statistical analysis; step 6, optimization of radiotherapy sensitivity assessment method; step 7, mechanism research; step 8, construction of radiotherapy sensitivity prediction model; step 9, multicenter study verification.

[0007] In a preferred embodiment, the literature research is to read existing relevant literature and research reports, including the expression of Survivin, the mechanism content related to tumor proliferation and treatment response, and obtain previous research results and inspiration through careful analysis of the literature to provide guidance for subsequent experimental design.

[0008] In a preferred embodiment, the cell line experiment is conducted using a nasopharyngeal carcinoma cell line, and the effect of Survivin expression on radiotherapy sensitivity is observed by regulating the expression level of Survivin. A variety of cell lines with different expression levels are selected, and the sensitivity of the cells to radiotherapy is observed to change by expressing or silencing the Survivin gene. Cell survival assays, proliferation inhibition experiments, cell cycle analysis, and apoptosis detection methods are used to evaluate the cell response to radiotherapy.

[0009] In a preferred embodiment, the statistical analysis is to perform statistical analysis on experimental data and clinical data to determine the correlation between the expression level of Survivin and radiotherapy sensitivity, and evaluate its predictive value as a molecular marker, and perform data analysis for evaluation. The evaluation method is one or more of statistical hypothesis testing, correlation coefficient analysis, survival analysis, and ROC curve analysis. Through statistical analysis, the accuracy, sensitivity and specificity of Survivin as a marker of radiotherapy sensitivity of nasopharyngeal carcinoma are evaluated.

[0010] In a preferred embodiment, the radiotherapy sensitivity assessment method is optimized to consider feasible methods for radiotherapy sensitivity assessment and the impact on the action of Survivin, and different cell survival detection methods are tested. The detection method is one or more of the MTT method, CCK-8 method, and cell initialization measurement method. Cell cycle analysis and apoptosis detection are important indicators for assessing cell sensitivity to radiotherapy. Optimizing the selection of assessment methods and operating procedures helps to more accurately evaluate the efficacy of Survivin as a molecular marker of radiotherapy sensitivity.

[0011] In a preferred embodiment, the mechanism study is to deeply explore the mechanism of action of Survivin in the radiosensitivity of nasopharyngeal carcinoma, use transcriptomics and proteomics high-throughput technologies to study the gene expression profile and protein interaction network related to Survivin's response to radiotherapy, and further analyze the biological function and signaling pathway of Survivin in the regulation of radiosensitivity through pathway enrichment analysis and expression correlation analysis.

[0012] Beneficial effects of the present invention:

[0013] Through the study of the molecular marker Survivin, the sensitivity of nasopharyngeal carcinoma patients to radiotherapy can be more accurately assessed, helping doctors determine individualized treatment plans and improving the accuracy of prediction and evaluation of treatment effects;

[0014] In-depth research on the role of Survivin in nasopharyngeal carcinoma and its relationship with radiosensitivity can provide a scientific basis for individualized treatment, help formulate precise treatment plans, and improve patient treatment outcomes and survival rates.

[0015] Clinical sample validation and multi-center research validation can better apply laboratory research results to clinical practice, provide clinicians with more reliable basis for treatment decision-making, guide clinical practice, and promote the improvement of treatment level;

[0016] In-depth research on the mechanism of Survivin in the radiosensitivity of nasopharyngeal carcinoma will help reveal the mechanism of tumor resistance to radiotherapy, provide theoretical and practical basis for the design and development of new therapies, and promote the improvement of radiosensitivity and the development of new drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] FIG1 is a schematic diagram of a method for determining radiotherapy sensitivity of nasopharyngeal carcinoma according to the present invention;

[0018] FIG2 is a schematic diagram of a determination flow of a method for determining radiotherapy sensitivity of nasopharyngeal carcinoma according to the present invention. DETAILED DESCRIPTION

[0019] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the drawings. It is obvious that the described embodiments are only part of the embodiments of the present invention, but not all of the embodiments.

[0020] Referring to Figures 1-2, the present invention provides a method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma. The molecular marker is Survivin. Determining Survivin as a molecular marker for the radiotherapy sensitivity of nasopharyngeal carcinoma includes the following steps:

[0021] Step 1: Literature research;

[0022] Step 2, cell line experiments;

[0023] Step 3: Animal model experiment;

[0024] Step 4: Clinical sample verification;

[0025] Step 5, statistical analysis;

[0026] Step 6: Optimize the radiotherapy sensitivity assessment method;

[0027] Step 7: Mechanism research;

[0028] Step 8: Construction of radiotherapy sensitivity prediction model;

[0029] Step nine: Multicenter study verification.

[0030] Literature research involves reading existing relevant literature and research reports, including information on survivin expression and its mechanisms related to tumor proliferation and treatment response. By carefully analyzing the literature, we can obtain previous research results and inspiration to provide guidance for subsequent experimental design;

[0031] Cell line experiments were conducted using nasopharyngeal carcinoma cell lines. The effect of survivin expression on radiosensitivity was observed by regulating the expression level of survivin. Multiple cell lines with different expression levels were selected to express or silence the survivin gene to observe whether the cell sensitivity to radiotherapy was changed. Cell survival assays, proliferation inhibition experiments, cell cycle analysis, and apoptosis assays were used to evaluate the cell response to radiotherapy.

[0032] Animal model experiments involve using mice or other appropriate animal models to implant nasopharyngeal carcinoma cells into animals to form tumor models. Survivin expression is then regulated to observe the correlation between survivin expression levels and tumor response to radiotherapy. Volume measurement, histopathological examination, and survival analysis are used to assess tumor response to radiotherapy.

[0033] Clinical sample validation involves collecting clinical samples from nasopharyngeal carcinoma patients, detecting survivin expression levels using molecular biology methods, and analyzing the correlation between survivin expression and radiotherapy sensitivity and prognosis. Fresh tumor tissue samples or preserved tissue samples are selected for survivin expression detection using immunohistochemistry, real-time quantitative PCR, and protein microarray methods, and the patients' radiotherapy response and survival rate clinical indicators are analyzed.

[0034] Statistical analysis: Statistical analysis of experimental and clinical data was performed to determine the correlation between survivin expression levels and radiosensitivity, and to evaluate its predictive value as a molecular marker. Data analysis was performed using statistical hypothesis testing and correlation coefficient analysis. Statistical analysis was performed to evaluate the accuracy, sensitivity, and specificity of survivin as a marker of radiosensitivity in nasopharyngeal carcinoma.

[0035] Optimization of radiosensitivity assessment methods: To consider feasible methods for radiosensitivity assessment and their impact on the role of survivin, different cell survival assays were tested. The MTT assay was used. Cell cycle analysis and apoptosis assay are important indicators for assessing cell sensitivity to radiotherapy. Optimizing the selection of assessment methods and operating procedures will help to more accurately evaluate the effectiveness of survivin as a molecular marker of radiosensitivity.

[0036] Mechanistic studies To further explore the mechanism of action of Survivin in nasopharyngeal carcinoma radiosensitivity, high-throughput transcriptomics and proteomics technologies were used to study the gene expression profile and protein interaction network related to Survivin's response to radiotherapy. Pathway enrichment analysis and expression correlation analysis were used to further elucidate the biological function and signaling pathway of Survivin in regulating radiosensitivity.

[0037] The radiotherapy sensitivity prediction model was constructed by combining experimental and clinical data, using bioinformatics and machine learning methods to construct a prediction model related to survivin and radiotherapy sensitivity. A feature selection algorithm based on survivin expression and other related factors was used to select the most relevant features to construct the model. The model was a support vector machine, and cross-validation and AUC value methods were used to evaluate and verify the model.

[0038] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. A method for determining the radiosensitivity of nasopharyngeal carcinoma, characterized in that: The molecular marker is Survivin. The steps for determining Survivin as a molecular marker for the radiosensitivity of nasopharyngeal carcinoma include the following: Step 1: Literature research; Step 2: Cell line experiments; Step 3: Animal model experiments; Step 4: Clinical sample verification; Step 5: Statistical analysis; Step 6: Optimization of the radiosensitivity assessment method; Step 7: Mechanism research; Step 8: Construction of a radiosensitivity prediction model; Step 9: Verification through multi-center research.

2. The method for determining the radiosensitivity of nasopharyngeal carcinoma radiotherapy according to claim 1, wherein: The literature research involves reading existing relevant literature and research reports, including the expression of Survivin and the mechanism content related to tumor proliferation and treatment response. By carefully analyzing the literature, previous research results and inspiration are obtained to provide guidance for subsequent experimental design.

3. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The cell line experiments are conducted using nasopharyngeal carcinoma cell lines. By regulating the expression level of Survivin, its effect on radiosensitivity is observed. Multiple cell lines with different expression levels are selected. By expressing or silencing the Survivin gene, whether the radiosensitivity of the cells changes is observed. Cell survival detection, proliferation inhibition experiments, cell cycle analysis, and apoptosis detection methods are used to evaluate the response of the cells to radiotherapy.

4. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The animal model experiments are conducted using mice or other suitable animal models. Nasopharyngeal carcinoma cells are implanted into the animals to form a tumor model. The expression of Survivin is regulated, and the correlation between the expression level of Survivin and the response of the tumor to radiotherapy is observed. Volume measurement, histopathological detection, and survival analysis methods are used to evaluate the response of the tumor to radiotherapy.

5. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The clinical sample verification involves collecting clinical samples of nasopharyngeal carcinoma patients. The expression level of Survivin is detected by molecular biology methods, and a correlation analysis is performed with the radiosensitivity and prognosis of the patients. Fresh tumor tissue samples or preserved tissue samples are selected. The expression level of Survivin is detected by immunohistochemistry, real-time quantitative PCR, and protein chip methods, and the clinical indicators such as the radiotherapy response and survival rate of the patients are analyzed.

6. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The statistical analysis involves performing statistical analysis on experimental data and clinical data to determine the correlation between the expression level of Survivin and radiosensitivity, and to evaluate its predictive value as a molecular marker. Data analysis is performed for evaluation. The evaluation means include one or more of statistical hypothesis testing, correlation coefficient analysis, survival analysis, and ROC curve analysis. Through statistical analysis, the accuracy, sensitivity, and specificity of Survivin as a radiosensitivity marker for nasopharyngeal carcinoma are evaluated.

7. The method for determining the radiosensitivity of nasopharyngeal carcinoma radiotherapy according to claim 1, wherein: The optimization of the radiosensitivity assessment method considers feasible methods for radiosensitivity assessment and the influence on the role of Survivin, and different cell survival detection methods are tested. The detection methods include one or more of the MTT method, CCK-8 method, and cell initialization measurement method. Cell cycle analysis and apoptosis detection are important indicators for evaluating the radiosensitivity of cells.

8. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The mechanism study was to deeply explore the mechanism of Survivin in the radiosensitivity of nasopharyngeal carcinoma. High-throughput techniques of transcriptomics and proteomics were used to study the gene expression profiles and protein interaction networks related to the radiotherapy response of Survivin. Through pathway enrichment analysis and expression correlation analysis, the biological functions and signal pathways of Survivin in the regulation of radiosensitivity were further analyzed.

9. The method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma according to claim 1, characterized in that: The construction of the radiosensitivity prediction model was to combine experimental and clinical data, and use bioinformatics and machine learning methods to construct a prediction model related to Survivin and radiosensitivity. A feature selection algorithm based on Survivin expression and other relevant factors was used to select the most relevant features to construct the model. The model was one or more of support vector machine, random forest, and logistic regression. Cross-validation and AUC value methods were used to evaluate and validate the model.

10. A method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma as described in claim 1, characterized in that: The multi-center study validation was to conduct a validation study in nasopharyngeal carcinoma patients in multiple medical institutions and different regions to increase the sample size and external validation ability. Collaborate with other laboratories or research teams to share clinical samples and data and conduct independent validation studies.

Images